ICYMI, this week we had news about the completion of LEO Pharma's acquisition of Timber Pharmaceuticals, research pointing to melanoma overdiagnosis in White patients, artificial intelligence in skin cancer detection, and more.
The VISIBLE clinical program will create a longitudinal collection of more than 20,000 clinical images across all skin tones.
In a recent study, prenatal opioid exposure was also linked to increased odds of infections and asthma, but not with allergies, anaphylaxis, or autoimmune conditions.
Zoryve was approved for the treatment of seborrheic dermatitis in patients ages 9 years and older in December.
Researchers also found that explainable AI methods, also known as XAI, further contributed to the confidence and accuracy associated with AI assistance.
A recent review evaluated the role of camouflage and concealment techniques and their role in improving the well-being of Black women with hair loss.
DermTech’s study results demonstrated that in patients with Fitzpatrick skin types IV-VI, all 3 melanomas diagnosed by histopathology were correctly identified by the 2-GEP assay as positive for LINC00518 and PRAME.
Subjects who received Sculptra treatments reported improvement in skin radiance and firmness.
A study explored the prioritization habits of both patients with atopic dermatitis and their caregivers when it comes to treatment.
Among dermatologists specializing in pediatric alopecia areata, a survey found that class 1 and 2 topical corticosteroids are the preferred first-line therapy.
The finalized acquisition comes 5 months after Timber Pharmaceuticals filed for chapter 11 bankruptcy.
Approximately half of patients presenting to dermatology clinics in Beirut reported the use of sunscreen.
89% of white men and 85% of white women who received a diagnosis of melanoma in 2018 were likely overdiagnosed, according to a new study.
Advancements in assistance from artificial intelligence include ambient listening to take notes during physician and patient conversations.
Click here to answer this week's poll.
Online patient recruitment methods were effective in a proof-of-concept trial involving patients with low-grade AK.
PeDRA has awarded more than $1.8 million to researchers, and deadlines to apply for the next round of grants are coming soon.
Investigators explained how the trial is structured to inhibit facial sebum production and inflammation among nearly 500 study participants.
In a recent Dermatology Times Case-Based Roundtable Meeting, Tina Bhutani, MD, MAS, shared intriguing cases and insights about atopic dermatitis treatment challenges faced by patients with different lifestyles and hobbies.
A poster presented at Maui Derm Hawaii delved into the efficacy and safety of trifarotene 50µg/g cream in acne vulgaris and PIH.
Researchers from Pyeongchon, Korea, argue that evidence points to the need for a change in the terminology of "freckling," according to a poster from Maui Derm Hawaii.
This article delves into 5 critical areas that dermatologists should focus on for a comprehensive 2024 report card.
In this week’s Pointers With Portela, the 208SkinDoc reviews various treatment methods for permanent wart removal.
Patients with moderate to severe AD gave their opinions in a survey on treatment options and their tradeoffs. Itch control topped the list of patient concerns.
A poster from Maui Derm Hawaii revealed an even more significant disparity than researchers anticipated.
A patient's social media post has gone viral and has been seen by thousands. Dr Derm is concerned this malicious act may ruin his career. What can he do?
A poster analyzing the BRAVE-AA study population was presented at Maui Derm Hawaii 2024.
So far, 2024 is shaping up to be just as busy as 2023 with new dermatology innovations, approvals, and data. Review what's still to come in 2024.
The novel nanofiber-based system holds promise for future nanotech applications in health care, researchers claim.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.